Efficacy with Trastuzumab Deruxtecan for Non-Small-Cell Lung Cancer Harboring HER2 Exon 20 Insertion Mutation in a Patient with a Poor Performance Status: A Case Report

Yuki Kato,1 Yasuhiro Kato,1 Yuji Minegishi,1,2 Takahiro Suzuki,1 Shinji Nakamichi,1 Masaru Matsumoto,1 Akihiko Miyanaga,1 Rintaro Noro,1 Kaoru Kubota,1 Yasuhiro Terasaki,3 Masahiro Seike,1 Akihiko Gemma1 1Department of Pulmonary Medicine and Oncology, Graduate School of Medicine, Nippon Medical Scho...

Descripción completa

Guardado en:
Detalles Bibliográficos
Autores principales: Kato Y, Minegishi Y, Suzuki T, Nakamichi S, Matsumoto M, Miyanaga A, Noro R, Kubota K, Terasaki Y, Seike M, Gemma A
Formato: article
Lenguaje:EN
Publicado: Dove Medical Press 2021
Materias:
Acceso en línea:https://doaj.org/article/42a3fb5282a946ddace0dd322e9a672c
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
id oai:doaj.org-article:42a3fb5282a946ddace0dd322e9a672c
record_format dspace
spelling oai:doaj.org-article:42a3fb5282a946ddace0dd322e9a672c2021-11-23T18:43:00ZEfficacy with Trastuzumab Deruxtecan for Non-Small-Cell Lung Cancer Harboring HER2 Exon 20 Insertion Mutation in a Patient with a Poor Performance Status: A Case Report1178-6930https://doaj.org/article/42a3fb5282a946ddace0dd322e9a672c2021-11-01T00:00:00Zhttps://www.dovepress.com/efficacy-with-trastuzumab-deruxtecan-for-non-small-cell-lung-cancer-ha-peer-reviewed-fulltext-article-OTThttps://doaj.org/toc/1178-6930Yuki Kato,1 Yasuhiro Kato,1 Yuji Minegishi,1,2 Takahiro Suzuki,1 Shinji Nakamichi,1 Masaru Matsumoto,1 Akihiko Miyanaga,1 Rintaro Noro,1 Kaoru Kubota,1 Yasuhiro Terasaki,3 Masahiro Seike,1 Akihiko Gemma1 1Department of Pulmonary Medicine and Oncology, Graduate School of Medicine, Nippon Medical School, Tokyo, Japan; 2Department of Pulmonary Medicine, Mitsui Memorial Hospital, Tokyo, Japan; 3Department of Analytic Human Pathology, Nippon Medical School, Tokyo, JapanCorrespondence: Yasuhiro KatoDepartment of Pulmonary Medicine and Oncology, Graduate School of Medicine, Nippon Medical School, Sendagi 1-1-5 Bunkyo-ku, Tokyo, 113-8603, JapanEmail y-kato@nms.ac.jpAbstract: Antibody–drug conjugate (ADC) was novel type of anticancer drugs. Trastuzumab deruxtecan (T-DXd), a human epidermal growth factor receptor 2 (HER2) targeting ADC, can be a novel treatment option for HER2 alternation (mutation, expression, amplification) advanced-stage non-small-cell lung cancer (NSCLC) from DESTINY-Lung01 result. Herein, we report a successful treatment with T-DXd for NSCLC harboring HER2 exon 20 insertion mutation in a patient with poor performance status (PS). We presented a case of a 52-year-old heavily pretreated female patient diagnosed with lung adenocarcinoma (cT1bN3M0, stage IIIB). After fifth-line pretreatment of systemic chemotherapy, primary tumor recurrence, pleural effusion, and miliary lung metastases were observed. The patient presented with hypoxia requiring oxygen therapy via nasal cannula at a flow rate of 4 L per minute, cancer pain, and cachexia requiring opioid treatment. Her Eastern Cooperative Oncology Group PS score was assessed 3. Comprehensive genomic profiling revealed HER2 exon 20 insertion mutation. After treatment with T-DXd was approved by the ethical review committee of Nippon Medical School Hospital, treatment was started. The tumor size decreased significantly, and her PS score decreased from 3 to 1, with improvement of hypoxia, cancer pain, and cachexia. The patient is still receiving treatment, without disease progression 6 months after starting treatment with T-DXd. Despite cases of poor PS, NGS should be performed and target therapy including ADCs should be considered.Keywords: lung cancer, HER2 exon 20 insertion mutation, poor PS, trastuzumab deruxtecanKato YKato YMinegishi YSuzuki TNakamichi SMatsumoto MMiyanaga ANoro RKubota KTerasaki YSeike MGemma ADove Medical Pressarticlelung cancerher2 exon20 insertion mutationpoor pstrastuzumab deruxtecanNeoplasms. Tumors. Oncology. Including cancer and carcinogensRC254-282ENOncoTargets and Therapy, Vol Volume 14, Pp 5315-5319 (2021)
institution DOAJ
collection DOAJ
language EN
topic lung cancer
her2 exon20 insertion mutation
poor ps
trastuzumab deruxtecan
Neoplasms. Tumors. Oncology. Including cancer and carcinogens
RC254-282
spellingShingle lung cancer
her2 exon20 insertion mutation
poor ps
trastuzumab deruxtecan
Neoplasms. Tumors. Oncology. Including cancer and carcinogens
RC254-282
Kato Y
Kato Y
Minegishi Y
Suzuki T
Nakamichi S
Matsumoto M
Miyanaga A
Noro R
Kubota K
Terasaki Y
Seike M
Gemma A
Efficacy with Trastuzumab Deruxtecan for Non-Small-Cell Lung Cancer Harboring HER2 Exon 20 Insertion Mutation in a Patient with a Poor Performance Status: A Case Report
description Yuki Kato,1 Yasuhiro Kato,1 Yuji Minegishi,1,2 Takahiro Suzuki,1 Shinji Nakamichi,1 Masaru Matsumoto,1 Akihiko Miyanaga,1 Rintaro Noro,1 Kaoru Kubota,1 Yasuhiro Terasaki,3 Masahiro Seike,1 Akihiko Gemma1 1Department of Pulmonary Medicine and Oncology, Graduate School of Medicine, Nippon Medical School, Tokyo, Japan; 2Department of Pulmonary Medicine, Mitsui Memorial Hospital, Tokyo, Japan; 3Department of Analytic Human Pathology, Nippon Medical School, Tokyo, JapanCorrespondence: Yasuhiro KatoDepartment of Pulmonary Medicine and Oncology, Graduate School of Medicine, Nippon Medical School, Sendagi 1-1-5 Bunkyo-ku, Tokyo, 113-8603, JapanEmail y-kato@nms.ac.jpAbstract: Antibody–drug conjugate (ADC) was novel type of anticancer drugs. Trastuzumab deruxtecan (T-DXd), a human epidermal growth factor receptor 2 (HER2) targeting ADC, can be a novel treatment option for HER2 alternation (mutation, expression, amplification) advanced-stage non-small-cell lung cancer (NSCLC) from DESTINY-Lung01 result. Herein, we report a successful treatment with T-DXd for NSCLC harboring HER2 exon 20 insertion mutation in a patient with poor performance status (PS). We presented a case of a 52-year-old heavily pretreated female patient diagnosed with lung adenocarcinoma (cT1bN3M0, stage IIIB). After fifth-line pretreatment of systemic chemotherapy, primary tumor recurrence, pleural effusion, and miliary lung metastases were observed. The patient presented with hypoxia requiring oxygen therapy via nasal cannula at a flow rate of 4 L per minute, cancer pain, and cachexia requiring opioid treatment. Her Eastern Cooperative Oncology Group PS score was assessed 3. Comprehensive genomic profiling revealed HER2 exon 20 insertion mutation. After treatment with T-DXd was approved by the ethical review committee of Nippon Medical School Hospital, treatment was started. The tumor size decreased significantly, and her PS score decreased from 3 to 1, with improvement of hypoxia, cancer pain, and cachexia. The patient is still receiving treatment, without disease progression 6 months after starting treatment with T-DXd. Despite cases of poor PS, NGS should be performed and target therapy including ADCs should be considered.Keywords: lung cancer, HER2 exon 20 insertion mutation, poor PS, trastuzumab deruxtecan
format article
author Kato Y
Kato Y
Minegishi Y
Suzuki T
Nakamichi S
Matsumoto M
Miyanaga A
Noro R
Kubota K
Terasaki Y
Seike M
Gemma A
author_facet Kato Y
Kato Y
Minegishi Y
Suzuki T
Nakamichi S
Matsumoto M
Miyanaga A
Noro R
Kubota K
Terasaki Y
Seike M
Gemma A
author_sort Kato Y
title Efficacy with Trastuzumab Deruxtecan for Non-Small-Cell Lung Cancer Harboring HER2 Exon 20 Insertion Mutation in a Patient with a Poor Performance Status: A Case Report
title_short Efficacy with Trastuzumab Deruxtecan for Non-Small-Cell Lung Cancer Harboring HER2 Exon 20 Insertion Mutation in a Patient with a Poor Performance Status: A Case Report
title_full Efficacy with Trastuzumab Deruxtecan for Non-Small-Cell Lung Cancer Harboring HER2 Exon 20 Insertion Mutation in a Patient with a Poor Performance Status: A Case Report
title_fullStr Efficacy with Trastuzumab Deruxtecan for Non-Small-Cell Lung Cancer Harboring HER2 Exon 20 Insertion Mutation in a Patient with a Poor Performance Status: A Case Report
title_full_unstemmed Efficacy with Trastuzumab Deruxtecan for Non-Small-Cell Lung Cancer Harboring HER2 Exon 20 Insertion Mutation in a Patient with a Poor Performance Status: A Case Report
title_sort efficacy with trastuzumab deruxtecan for non-small-cell lung cancer harboring her2 exon 20 insertion mutation in a patient with a poor performance status: a case report
publisher Dove Medical Press
publishDate 2021
url https://doaj.org/article/42a3fb5282a946ddace0dd322e9a672c
work_keys_str_mv AT katoy efficacywithtrastuzumabderuxtecanfornonsmallcelllungcancerharboringher2exon20insertionmutationinapatientwithapoorperformancestatusacasereport
AT katoy efficacywithtrastuzumabderuxtecanfornonsmallcelllungcancerharboringher2exon20insertionmutationinapatientwithapoorperformancestatusacasereport
AT minegishiy efficacywithtrastuzumabderuxtecanfornonsmallcelllungcancerharboringher2exon20insertionmutationinapatientwithapoorperformancestatusacasereport
AT suzukit efficacywithtrastuzumabderuxtecanfornonsmallcelllungcancerharboringher2exon20insertionmutationinapatientwithapoorperformancestatusacasereport
AT nakamichis efficacywithtrastuzumabderuxtecanfornonsmallcelllungcancerharboringher2exon20insertionmutationinapatientwithapoorperformancestatusacasereport
AT matsumotom efficacywithtrastuzumabderuxtecanfornonsmallcelllungcancerharboringher2exon20insertionmutationinapatientwithapoorperformancestatusacasereport
AT miyanagaa efficacywithtrastuzumabderuxtecanfornonsmallcelllungcancerharboringher2exon20insertionmutationinapatientwithapoorperformancestatusacasereport
AT noror efficacywithtrastuzumabderuxtecanfornonsmallcelllungcancerharboringher2exon20insertionmutationinapatientwithapoorperformancestatusacasereport
AT kubotak efficacywithtrastuzumabderuxtecanfornonsmallcelllungcancerharboringher2exon20insertionmutationinapatientwithapoorperformancestatusacasereport
AT terasakiy efficacywithtrastuzumabderuxtecanfornonsmallcelllungcancerharboringher2exon20insertionmutationinapatientwithapoorperformancestatusacasereport
AT seikem efficacywithtrastuzumabderuxtecanfornonsmallcelllungcancerharboringher2exon20insertionmutationinapatientwithapoorperformancestatusacasereport
AT gemmaa efficacywithtrastuzumabderuxtecanfornonsmallcelllungcancerharboringher2exon20insertionmutationinapatientwithapoorperformancestatusacasereport
_version_ 1718416149886009344